Article Text

other Versions

PDF
PCP prophylaxis with use of corticosteroids by neurologists
  1. Dearbhla M Kelly1,
  2. Simon Cronin1,2
  1. 1Department of Neurology, Cork University Hospital, Cork, Ireland
  2. 2Department of Clinical Neuroscience, College of Medicine and Health, University College Cork, Cork, Ireland
  1. Correspondence to Dr Simon Cronin, Department of Neurology, Cork University Hospital, Cork, Ireland; simon.cronin{at}hse.ie

Abstract

Pneumocystis jirovecii pneumonia (PCP) is increasingly reported in patients without HIV. Corticosteroids are a major risk factor, with up to 90% of patients receiving corticosteroid treatment prior to the development of PCP. In view of this, many specialties now prescribe PCP prophylaxis to patients receiving prolonged or high-dose glucocorticoid regimens. Neurologists frequently prescribe corticosteroids but may not be as aware of the risk for PCP. Here, we review the evidence for routine PCP prophylaxis among regular glucocorticoid users and ask what guidance there is on the subject for neurologists.

  • CLINICAL NEUROLOGY
  • STEROIDS

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editors' choice
    Phil Smith and Geraint N Fuller